Generalization and representativeness of phase III immune checkpoint blockade trials in non‐small cell lung cancer-Reference-Cited by-同舟云学术

Generalization and representativeness of phase III immune checkpoint blockade trials in non‐small cell lung cancer

Published:2018-04-22 Issue:6 Volume:9 Page:736-744
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thorac Cancer

Author:

Yoo Shin Hye¹,Keam Bhumsuk¹²^ORCID,Kim Miso¹,Kim Tae Min¹²,Kim Dong‐Wan¹²,Heo Dae Seog¹²

Affiliation:

1. Department of Internal MedicineSeoul National University Hospital Seoul South Korea

2. Cancer Research InstituteSeoul National University College of Medicine Seoul South Korea

Funder

Korea Health Industry Development Institute

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.12641

Reference32 articles.

1. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

2. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

3. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

4. National Comprehensive Cancer Network.Non‐Small Cell Lung Cancer (version 6. 2017).2017[Cited 9 Feb 2018.] Available from URL:http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.

5. Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quantitative evaluation of the impact of relaxing eligibility criteria on the risk–benefit profile of drugs for lung cancer based on real‐world data;Thoracic Cancer;2024-04-04

2. Let's Talk About Sex: Survival Among Females and Males in a Real-World Cohort Treated with Pembrolizumab for Non-Small Cell Lung Cancer;2024

3. Checkpoint inhibitor monotherapy in potentially trial-eligible or trial-ineligible metastatic NSCLC patients in the German prospective CRISP Registry real-world cohort (AIO-TRK-0315);JTO Clinical and Research Reports;2023-12

4. Health outcomes and healthcare resource utilization among Veterans with stage IV non-small cell lung cancer treated with second-line chemotherapy versus immunotherapy;PLOS ONE;2023-02-21

5. Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy in Patients With Metastatic Colorectal Cancer With Measures of Microsatellite Instability, Mismatch Repair, or Tumor Mutational Burden;JAMA Network Open;2023-01-23